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Abstract
Background: Schizophrenia is understood to be a heterogeneous brain condition with overlapping symptom
dimensions. The negative symptom dimension, with its protean cognitive manifestations, responds poorly to
treatment, which can be a particular challenge in countries where clozapine therapy is not available. Preliminary
data indicate that minocycline may be beneficial adjunct in the treatment of schizophrenia: positive, negative, and
cognitive symptoms.
In this study we aim to assess the efficacy of adjunctive minocycline to alleviate symptoms of schizophrenia in
patients who have failed to respond to a therapeutic trial of antipsychotic medications.
Methods: The study is a parallel group, double-blind, randomized, placebo-controlled trial. Participants will be
adults (aged 18 years and above) with first episode or relapse episode of schizophrenia of under 5 years’ duration.
Patients who failed to show adequate therapeutic response to at least one antipsychotic medication given for a
minimum of 4 weeks will be recruited from a psychiatry hospital in Addis Ababa and a psychiatry clinic in Butajira,
Ethiopia. A total of 150 participants (75 in each arm) will be required to detect a five-point mean difference between
the intervention arms adjusting for baseline symptom severity, at 90% power and 95% confidence. Patients in the
intervention arm will receive minocycline (200 mg/day orally) added on to the regular antipsychotic medications
participants are already on. Those in the placebo arm will receive an inactive compound identical in physical appearance
to minocycline. Intervention will be offered for 12 weeks. Diagnosis will be established using the operational criteria for
research (OPCRIT). Primary outcome measure will be a change in symptom severity measured using the positive and the
negative syndrome scale for schizophrenia (PANSS). Secondary outcome measures will include changes in severity of
negative symptoms, proportion achieving remission, and level of functioning. Whether changes are maintained post
intervention will also be measured (PANSS). Key assessment for the primary outcome will be conducted at the end of
trial (week 12). One post-intervention assessment will be conducted 4 weeks after the end of intervention (week 16) to
determine sustainability of change.
Trial registration: Clinicaltrials.gov identifier: NCT01809158.
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Schizophrenia is a severe mental disorder associated
with substantial morbidity and burden. For many indi-
viduals it causes a lifelong disability at immense cost to
family and society [1]. Schizophrenia is accepted to be a
heterogeneous brain disorder with undetermined etiology.
The conceptualization of schizophrenia has evolved over
the past century, since its distinction from affective psych-
osis. The diagnosis rests on the combination of the oc-
currence of typical clinical features and longitudinal
observation. Based on the clinical features, three overlap-
ping dimensions of schizophrenia are identified: positive,
negative, and disorganized [2,3]. These dimensions have a
significant bearing on the course of the disorder: those
with negative symptoms have poorer treatment response
and more unfavorable course. Negative symptoms are par-
ticularly associated with various cognitive impairments
that may lead to poor treatment response.
Although the introduction of antipsychotic medication
almost half a century ago was undoubtedly a huge step
forward in the treatment of schizophrenia [4], a large
proportion of patients fail to respond satisfactorily to tri-
als with antipsychotic medications. For example, a study
of 1,400 people with schizophrenia from 52 diverse sites
across the United States found that only 14.5% partici-
pate in gainful employment, 12.9% report work in work-
shops or rehabilitation programs, and 72.6% reported
no employment [5]. In the past 15 years, several new
medications called second generation or atypical anti-
psychotics have been introduced for the treatment of
schizophrenia. These new generation antipsychotic med-
ications have shown substantially fewer extrapyramidal
side effects (EPSE) than first generation antipsychotic
medications, which are the mainstay of treatment in low
income countries like Ethiopia. However, these second
generation antipsychotics are not shown to be clinically
more effective than first generation antipsychotics [6]
and are associated with metabolic side effects. The only
second generation antipsychotic medication which has
been shown to be clinically more effective and to reduce
rates of hospitalization is clozapine [7,8]. Moreover, the
side effect burden of clozapine is high and clozapine is
not available in many low income countries, including
Ethiopia.
Preliminary data indicate that minocycline, a safe
semi-synthetic tetracycline, may have neuroprotective
properties and efficacy in improving negative symptoms
of schizophrenia. Minocycline may be particularly relevant
in low income countries, where it has been hypothesized
that infectious agents contributing to the presentation of
schizophrenia may be more common. In this study we
aim to assess the efficacy of minocycline to alleviate symp-
toms of schizophrenia when given as an adjuvant to
ongoing antipsychotic treatment.
Minocycline: nature
Minocycline is a tetracycline compound with activity as a
broad spectrum bacteriostatic antibiotic. Minocycline
is intrinsically more active against gram-positive than
gram-negativemicro-organisms. It is also effective against
micro-organisms such as rickettisia, coxiellaburnetti, myco-
plasmapneuomniae, chlamydia species, legionella species,
ureaplasma, some atypical mycobacteria, and plasmo-
dium species. It is also active against many spirochetes,
including borrelia burgdorferi (lyme disease) and trepo-
nema pallidum (syphilis). Minocycline inhibits bacterial
protein synthesis by binding to the 30s bacteria ribo-
some and preventing access of aminoacyl tRNA to the
acceptor (A) site on the mRNA-ribosome complex [9].
After an oral dosing, mincycline is almost completely
absorbed and has a half-life of 16 to 18 h. It can there-
fore be administered less frequently and at lower doses.
Importantly, unlike many other tetracyclines, food (includ-
ing dairy products) does not interfere with the absorption
of minocycline. It is significantly metabolized by the liver
and is recovered from the urine and feces in lower
amounts than other tetracyclines. The t1/2 of minocycline
is not prolonged in patients with hepatic failure. The usual
dose of minocycline is 100 mg every 12 h.
Minocycline is a well tolerated medication although
some of the general side effects related to tetracyclines
may occur. Gastro-intestinal irritation may occur but
improves when administered with food. Hepatic toxicity
typically develops in patients receiving large quantities
orally. Minocycline may aggravate azotemia in patients
with renal disease. Brown discoloration of teeth may also
occur if given between the ages of 2 months and 5 years.
Treatment with tetracycline during pregnancy may also
be associated with tooth discoloration in the child. Pa-
tients taking minocycline may also experience some ves-
tibular toxicity, manifested by dizziness, ataxia, nausea,
and vomiting. Symptoms occur soon after the initial
dose and usually disappear within 1 to 2 days after drug
cessation. Hypersensitivity rarely occurs.
Minocycline for neurodegenerative diseases and
schizophrenia
Minocycline has excellent penetration of the blood–
brain barrier and is believed to modulate inflammatory
processes linked to the pathophysiological mechanisms
relevant to the onset or progression of neurodegenera-
tive diseases [10] and schizophrenia [11].
Reviewing the potential benefits of minocycline in
mental disorders and schizophrenia, four pathways,
which were linked to the causation of mental disorders,
have been proposed [11]. The first mechanism is the
calcium mediated glutamate excitotoxicity. Increased glu-
tamate modulated intracellular calcium has been linked
with mood and psychotic disorders, and minocycline was
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animal models. In one study, minocycline attenuated the
behavioral changes following the administration of an
NMDA antagonist in mice [12]. In another study, minocy-
cline reversed the effects of an NMDA antagonist in rats
[13]. The second mechanism highlighted relates to the
antioxidant properties of minocycline. Minocylcine dir-
ectly scavenges free radicals and inhibits molecules such
as cyclooxygenase 2, induced nitric oxide synthase, and
nicotinamide adenine dinucleotide phosphate oxidase.
The third mechanism refers to the nuroprotective proper-
ties of minocycline, for example, through the caspase-
independent anti-apoptotic effects including upregulation
of antiapoptotic factor BCL-2 [14]. The fourth pathway
relates to the anti-inflammatory properties of minocycline.
In a mechanism that seems to be distinct from its anti-
microbial properties, minocycline has anti-inflammatory
and neuroprotective properties [15].
Even though the role of microgilia in the neruo-
inlammatory process is not fully confirmed [16], the
anti-inflammatory activity of minocycline is attributed
partly to its capacity to suppresses neuroimmune activa-
tion/proliferation of microglia as well as subsequent
release of proinflammatory cytokines such as interleukins,
IL-1β and IL-6, and tumor necrosis factor (TNF-α), neu-
rotoxic substances such as nitric oxide, ROS, and chemo-
kines [14]. Furthermore, the cyoprotective activity of
minocycline other inflammatory mediators such as the
blockade of enzymatic activity of mitogen activated pro-
tein kinase 38 (P38 MAPK) which is thought to mediate
inflammatory responses and cell death [17,18]. Minocy-
cline is also linked with the inhibition of caspase-1 and
caspase-3, which are involved in the generation of
interleukin-1 and apoptosis, respectively [19]. Minocycline
is reported to suppress the release of lipids and the activity
of matrix metalloproteases (MMPs), which disrupt the
blood–brain barrier [19]. Minocycline was also found to
reduce prostaglandin-E2 (PGE2) formation and inhibit
cyclo-oxygenase-2 (COX-2) expression in murine mi-
croglia and prostaglandin F2a (PGF2a) and PGE2 pro-
duction induced by LPS in primary rat microglial cells
[11]. Minocycline has also been reported to have antiviral
effects against HIV and antiprotozoal effects against
Toxoplasmagondii.
Its use in individuals with schizophrenia has been en-
couraged by its effects in rodent models of this disorder.
Some preliminary data also suggest that minocycline
may be useful in patients with schizophrenia. Two case
report series have been published, one including two pa-
tients with schizophrenia [20] and the other including
three patients with recent-onset acute paranoid schizo-
phrenia [21]. An open label study of 22 patients with
treatment-resistant schizophrenia, using minocycline
150 mg/d for 4 weeks, reported an improvement in both
positive and negative symptoms [15,22]. Two double-
blind trials have been carried out. In one study, 73
patients with schizophrenia of <5 years’ duration were
randomized to minocycline 200 mg or placebo for
12 months: ‘all symptom measures improved significantly’
especially in the negative symptoms [23]. In the other
study, 54 ‘early phase’ (symptoms of <5 years) patients
were randomized to minocycline 200 mg/d or placebo for
6 months; the authors reported a significant improvement
in negative symptoms measured using Scale for the
Assessment of Negative Symptoms (SANS) and Clinical
Global Impression (CGI) and a significant improvement in
some test of executive function [24].
These initial findings encourage further replication.
First, these studies are of comparatively small size.
Second, in countries like Ethiopia where options for the
treatment of schizophrenia are limited, identifying a safe
alternative to clozapine is important. Related to this,
most patients have limited exposure to psychotropic
medications. Third, exposure to alcohol and substances
is generally believed to be lower in the Ethiopian setting.
Finally, given our hypothesis that infectious agents as a
cause of schizophrenia may be more important in low
income countries such as Ethiopia, minocycline may
prove more useful. In this regard, the trial will help to
explore the etiology of schizophrenia.
Study aim and objectives
The general aim of the study is to evaluate the efficacy
and tolerability of minocycline as an adjuvant medica-
tion for patients with schizophrenia, who have failed to
respond to an adequate trial of an antipsychotic medica-
tion defined as a dose equivalent to chlorpromazine of
at least 200 mg per day given for a minimum of 4 weeks.
The specific objectives of the study are to determine the
efficacy of minocycline added onto a standard treatment
of schizophrenia in improving symptoms of schizophrenia
(as measured by PANSS), global clinical state, negative
symptoms of schizophrenia, and general functioning; and
to assess the side effect burden of minocycline above and
beyond standard antipsychotic medications.
Hypothesis
Persons with early phase or recently relapsed schizophre-
nia who are prescribed minocycline in addition to stand-
ard antipsychotic medication will show greater symptom
reduction (measured with the PANSS) compared with
those taking standard antipsychotic medication alone.
Methods
Design
The study will be a double-blind, randomized, placebo-
controlled study of the efficacy of adjuvant minocycline
in reducing the severity of illness in treatment-resistant
Fekadu et al. Trials 2013, 14:406 Page 3 of 10
http://www.trialsjournal.com/content/14/1/406schizophrenia, compared with a placebo. The study will
be powered to detect a minimum of five-point difference
in PANSS or a minimum effect size of 0.31.
Study setting and participants
The trial will recruit patients from the inpatient and out-
patient units of Amanuel specialist psychiatric hospital in
Addis Ababa and a general hospital in Butajira, southern
Ethiopia. Amanuel hospital is the main institution for the
care of those with severe mental illness. The hospital runs
both inpatient and outpatient services. At the outpatient
service over 150,000 people with mental disorder, most
with severe mental illness, are seen every year. The in-
patient unit has around 280 beds. Analysis of data from
the inpatient unit indicates that most patients were admit-
ted with schizophrenia [25]. Recent changes in the service
structure of the hospital acknowledge this. Thus most of
the clinical service is geared towards providing care for
patients with schizophrenia. The hospital also serves as a
repository of most psychotropic medications. For example,
the Special Pharmacy holds various medications, including
atypical antipsychotics (risperidone and olanzapine) for
those able to pay for their medication.
Butajira hosts a large, population-based cohort study
looking at the outcome of severe mental disorders
(schizophrenia, bipolar disorder, and major depression)
[26-28]. The study, funded by the SMRI, has been run-
ning for just over 10 years. Most included in the cohort
are people with schizophrenia. Over 200 individuals with
schizophrenia are currently being followed up. This is a
well characterized cohort, with detailed clinical, func-
tional, and socio-demographic information.
Participants
To be eligible, potential participants have to be either
part of the Butajira study mentioned above or reside
within the study catchment area in Butajira. If recruited
from Amanuel hospital, they should be from Addis
Ababa. This is so that successful follow-up can be maxi-
mized. Specifically, consenting individuals fulfilling entry
criteria described below will be successively recruited.
Figure 1 depicts the overall recruitment procedure.
Participant inclusion criteria
1. Age 18 to 64 years
2. Primary Axis I diagnosis (DSM-IV) [29]o f
schizophrenia, any subtype
3. The current episode should be either a relapse
episode or a first onset schizophrenia and the
duration of the relapse episode and first onset
schizophrenia should be <5 years
4. Indication of treatment-resistance defined by failure
of at least one adequate dose of antipsychotic
medication (equivalent to chlorpromazine of
200 mg/day or more) given for at least 4 weeks. For
the minority of patients receiving second generation
antipsychotic medications, adequate doses will be
Risperidone 4 mg/day, or Olanzapine 10 mg/day
5. Presence of at least moderate severity of illness
measured according to the PANSS (score of at least
75 [30])
6. On adequate dose of antipsychotic medication at
point of recruitment
7. Both genders, but women have to be of non-child-
bearing age because of potential risks to pregnant
women, and the difficulty of ensuring contraception
Participant exclusion criteria
1. Substance abuse co-morbidity or history of substance
abuse/dependence within the previous 3 months
2. Impaired cognitive capacity because of a
degenerative brain condition or trauma or diagnosis
of mental retardation
3. Any serious medical condition that affects brain or
cognitive function (for example, epilepsy, serious
head injury, brain tumor, or other neurological and
neurodegenerative conditions)
4. Any clinically significant or unstable medical
disorder as determined by the trial physician that
would preclude study participation, including
congestive heart failure, abnormal liver function or
disease, renal impairment. Also patients with
leucopenia, anemia, and thrombocytopenia will be
excluded
5. History of hypersensitivity to tetracycline
6. Patients on anticoagulant therapy
7. Patients requiring ergot alkaloids
8. Patients taking antacids containing aluminum,
calcium, or magnesium, and products containing iron
9. Women of childbearing age (age 18 to 49 years)
10. Increased risk of suicide
Sample size
We used the Stata statistical program, version 11 (Stata-
Corp 2009) to compute the required sample size. From a
previous study [31], we estimated the average means
(SD) of active intervention and placebo group to be 79
(16.3). Furthermore, we assumed that a five-point differ-
ence between active intervention and placebo will be
clinically meaningful. This is based on a previous study,
which found a statistically and clinically significant
difference of five points on the PANSS comparing cloza-
pine and olanzapine [8]. With a correlation coefficient of
0.7 and a mean change of five points on PANSS using
Analysis of Co-variance (ANCOVA) method at three
measurement points, 90% power and 95% confidence, a
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20% loss, a total of 147 participants will be needed. We
therefore propose to recruit 150 participants (75 per arm).
Randomization procedure and treatment allocation
Randomization will be blinded to the treating clinician,
participating patients, and outcome assessors. Tablets
for each patient will be packed in advance. A computer-
ized system will be used to generate a randomization
list. The randomization is to be organized so that,
among each block of four individuals recruited to the
study, there will be two allocations to the minocycline
a r ma n dt w ot ot h ep l a c e b oa r m .F r o mt h er a n d o -
mization list, labeled and sealed envelopes will be
prepared containing cards with treatment allocation.
The applicable set of sealed envelopes will be handed
over to the designated senior pharmacist at Amanuel
hospital or Butajira hospital for participants recruited at
Amanuel and Butajira, respectively. These are to be kept
in a secure place. Only the pharmacist is permitted to
open the envelopes. Treatment allocation will be the
responsibility of the designated senior pharmacist.
Treatment schedules
All participants will continue their antipsychotic medica-
tion, which may be adjusted as required during the
follow-up monitoring. The active intervention, minocy-
cline, will be given at a dose of 100 mg 12-hourly. The
comparison group will receive an inactive placebo com-
pound of identical color, texture, and taste. The treat-
ments will be given for 12 weeks, which is within the
duration range of effective preliminary trials of minocy-
cline adjunctive therapies [15,21-23]. The usual treatment
will continue under the treating physician. Summary of
the recruitment and follow-up is depicted in the trial flow
diagram (Figure 1).
Trial medications will be dispensed on a 4-weekly basis
by the senior pharmacist. Treatment adherence will be
assessed through patient report and pill count. To assist
with this, participants will be requested to come back with
Declined to participate 
or excluded
Individuals with resistant 
schizophrenia
Minocycline 
200 mg/d
(N=75)
Informed consent 
Baseline investigations
RANDOMIZATION
Placebo
(N=75)
ARM 2
Blinded Clinical assessment: week 0,   week 6, week 12  
and week 16
ARM 1
Primary outcome: Change in mean PANSS score between 
baseline and week 8 
Secondary outcome: Change in negative symptom 
domain; Change in CGI score; Change in functioning; 
Adverse events
Figure 1 Adjunctive minocycline versus placebo: a trial flow diagram.
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coming for their follow-ups that coincide with medication
resupply.
Evaluation of treatment efficacy
The main assessments, as shown in Table 1, will be con-
ducted at four time points: at baseline (before the initiation
of trial medication), week 6, at the end of intervention
(week 12), and 4 weeks post intervention (week 16) to
evaluate whether changes have been maintained.
Assessments
Baseline assessments
Diagnostic assessment We will use the Operational
Criteria for Research (OPCRIT) [32] to make diagnosis
of schizophrenia. The OPCRIT is an operational criteria
checklist for psychotic disorders and is designed to be
used with a computer program. The instrument uses
some of the rating styles of the Schedules for Clinical
Assessment in Neuropsychiatry (SCAN) [33] but is briefer
and simpler to administer. It has established reliability and
allows application of multiple diagnostic criteria [32]. The
OPCRIT also allows diagnosis of co-morbid substance
abuse and personality disorder. It has a checklist of symp-
toms, which can either be printed out (a paper and pencil
version) or a computerized version, which together form
the OPCRIT system. The paper version will be adminis-
tered in a face-to-face interview and data will then be
transferred into the computer program. The checklist is
linked with extensive definitions that standardize each
item to be rated. The SCAN has been in use in Ethiopia
over many years administered by residents in psychiatry
and psychiatrists [27,28]. TS and AF have trained in the
application of the SCAN and have extensive experience in
administering the SCAN. AF has experience of using the
OPCRIT and has also provided training in the use of
the tool. The OPCRIT will be administered for partici-
pants from Addis Ababa. For participants from Butajira,
OPCRIT will be administered only for those who are not
part of the ongoing cohort study described above. Partici-
pants from the ongoing cohort have extensive clinical data
which includes SCAN diagnosis and additional diagnostic
assessment is not necessary. Selected socio-demographic
and clinical data will also be collected.
Physical assessment A thorough physical (and neuro-
logical) assessment will be conducted by qualified physi-
cians. We will also conduct liver function test, renal
function test, full blood count, and investigations that
may be relevant to the individual participant. The main
objective of this assessment is to determine factors that
may preclude use of minocycline.
Symptom severity assessment PANSS [34-36] will be
used as the main assessment instrument. PANSS is a
30-item semi-structured instrument widely used in the
research of schizophrenia. Each item is rated on a seven-
point severity continuum (1 to 7) and is completed using
all available information: interview of participant, infor-
mation from family, and clinical records. The scores pro-
vide several separate clinical subdomains but three
subscales have been found more consistently: the posi-
tive syndrome subscale, the negative syndrome subscale,
and the general psychopathology subscale [37]. These
subscales are said to be normally distributed and in-
dependent of each other; they were also found to be
‘robust to the effects of mood, chronicity, medication
side effects and cognition’ [37]. PANSS is also ‘sensitive
and specific’ to the effects of medication in both the
positive and negative symptoms of schizophrenia. The
other advantage of the PANSS is the consistency in rat-
ing patients over time and illness course [37]. It has been
successfully used in a trial in Ethiopia [31].
We will also use the CGI as a summary assessment of
the clinical state of the participant. The CGI is one of
the most widely used assessment tools to determine
overall illness severity and efficacy of intervention. The
instrument has three items which assess illness severity.
The scale is completed entirely based on clinical judg-
ment [37]. The current severity of illness is rated on a
seven-point score ranging from 1 (when the patient is
assessed to have no illness) to 7 (when the patient is
among the most severely ill). CGI also allows rating of
global improvement whether the improvement is caused
by medication or not. Again improvement is rated on a
Table 1 Summary of assessment schedule and rating
scales to be used
Rating
scales
Assessment
schedule
Baseline Wk 2 Wk 4 Wk 6 Wk 8 Wk 10 Wk 12 Wk 16
Height √
Weight √√
FBC √√ √
LFT √√ √
RFT √√ √
OPCRIT √
PANSS √√ √ √
GAF √√ √ √
CGI √√ √ √
AER √ √√√√√ √ √
AER= Adverse events rating; CGI = Clinical global impression; FBC= Full blood
count; LFT = Liver function test; GAF = Global assessment of functioning;
OPCRIT = Operational criteria for research; PANSS = Positive and negative
syndrome scale; RFT = Renal function test.
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proved) to 7 (very much worse). The final item of the
CGI helps rate overall efficacy of treatment as a factor of
the overall burden of side effect of medication. When
administered repeatedly it can evaluate treatment re-
sponse [38] and has been employed in numerous inter-
vention studies in schizophrenia. The CGI is sensitive to
change and its ‘brevity, utility and appeal to clinical
commonsense’ [37] makes it an attractive rating scale.
Functioning We will administer the Global Assessment
of Functioning (GAF) [29], a simple 100-point scale that
assesses both functioning and general psychopathology.
The scale is divided into 10-point intervals and the as-
sessor assigns a numeric value to the functioning status
of the participant.
Cognitive function The cognitive items of the PANSS
will be used to assess the impact of intervention on cog-
nitive function.
Follow-up assessment
The PANSS will be the main outcome measure. We will
also use the CGI and GAF. In addition to the key assess-
ment dates for primary outcome (baseline, week 6, and
week 12), participants will be assessed every 2 weeks to
monitor medication side effects. This assessment will be
conducted by telephone by a trained trial nurse. Partici-
pants will be invited to come to hospital if there are in-
dications of side effects on the telephone call. If the
person cannot be reached by telephone, a health exten-
sion worker (community health worker) within the dis-
trict will visit the person’s house to check. To facilitate
this process, all participants will be linked to health ex-
tension workers, who will also be trained on talking to
patients with mental illness and their families. To
maximize adherence to follow-up assessments, we will
also implement additional methods: (1) For participants
to be recruited from Butajira, we will use our existing
network of field workers and health extension workers
to encourage follow-up. (2) For patients to be recruited
from Addis Ababa: (a) we will only include persons with
clear and traceable address. For example, we will exclude
persons living in ‘NEW’ addresses. (b) We will use urban
health extension workers. (3) For both sites, we will offer
phone cards (Birr 15) to encourage contact by partici-
pants if they felt there was a clinical need to do so. We
will also call a day before their scheduled follow-up ap-
pointment date to remind them of the appointment.
Staff doing this will be trained to be courteous so that
participants are treated respectfully and also are not har-
assed to attend.
Assessors
PANSS, CGI, and GAF will be completed by either psychi-
atric nurses, masters-level trained psychiatry practitioners,
or psychiatry residents or psychiatrists depending on their
ability to conduct the assessments adequately after ad-
equate training and assessment of inter-rater reliability.
The OPCRIT will be administered by trained psychiatric
residents (at least second year) or qualified psychiatrists
after training. Physical assessment will be conducted ei-
ther by psychiatric residents or general physicians. The
OPCRIT will be initially validated against the SCAN.
We will also assess the validity of the assessment by psy-
chiatric nurses and residents, of all major instruments,
against senior psychiatrists, as well as inter-rater reliability
of assessments between the different professionals.
Outcome
Primary outcome
Attained mean symptom severity at week 12 (based on
total PANSS score) compared between the treatment arms;
measured over three assessment time points: at entry
(baseline), week 6, and end of intervention at 12 weeks.
Secondary outcomes
1. Change in severity of negative symptoms measured
as difference in PANSS score between entry (baseline)
assessment and end of intervention at 12 weeks.
2. Maintenance of change or improvement measured
between weeks 12 and 16.
3. Change in CGI scores from baseline to week 12,
measured as an absolute difference in scores.
4. Change in functioning measured using GAF from
baseline to 12 weeks as a function of the mean
difference in scores at the two time points.
5. Proportion attaining remission and time to attain
remission defined using PANSS as per the definition
of remission for schizophrenia [39].
6. Requirement of additional medication and dose
adjustment; proportion requiring these additions and
adjustments will be compared between the two arms.
7. Adverse effects of medications: proportion
developing adverse effects as a function of severity
will be compared in the two arms.
Tertiary outcome
Change in severity scores of the cognitive domain of the
PANSS between baseline and week 12 will be compared
between the treatment arms as a tertiary outcome.
Data management and analysis
Data management will be handled by the Clinical trial unit
at the Armauer Hanssen Research Institute (AHRI). This
includes setting up data entry profile, handling interim
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(DSMB), and final analysis for the primary outcome.
The primary analysis will be to compare the effect of
treatment with minocycline compared with placebo in
terms of attained mean symptom severity measured in
PANSS score at week 12. Mixed effects model will be
fitted to the PANSS score obtained at three time points
(at baseline, 6 weeks, and 12 weeks) and trial treatments
will be evaluated as a predictor of rate of change in
PANSS score and attained PANSS score at week 12
adjusting for relevant baselinep r o g n o s t i cf a c t o r s .T h e s e
factors, identified as relevant for schizophrenia out-
come, are duration of untreated psychosis, age of onset
of illness, duration of illness, gender, and setting of re-
cruitment (inpatient versus outpatient). Intention to
treat analysis will be performed on primary outcome.
Secondary analysis will also be comparative.
– Analysis of measures at two time points (baseline
and week 12 ) will compare absolute differences in
symptom and functional scores (negative
symptoms, GAF, CGI) between the treatment arms
adjusting for relevant prognostic factors as
proposed for the primary outcome.
– Profile of symptoms in the three domains of PANSS
will be compared using repeated measures model:
change and rate of change between the two
treatment arms will be assessed with the mixed
effects regression model.
– Time to remission will be computed using survival
model. This will use the Cox Regression model
adjusting for relevant prognostic factors as for the
primary outcome.
– Sustainability of improvement or change will be
measured as the proportion of those who have
maintained their improvement (including those who
have shown continued improvement) after 12 weeks
compared between the two treatment arms. This
comparison will rely on the PANSS, CGI, and GAF
scores.
Withdrawals and end of trial
Withdrawal from study may occur because of one of
three reasons: refusal of participant to continue in study,
occurrence of severe toxicity, and finally clear indication
that the intervention is very effective and should be
given to participants receiving placebo medication. In all
cases, analysis will be by intention to treat. All protocol
violations and major deviations will be recorded as they
occur and will be included in reports of trial findings.
The end of the trial will either be when the study period
ends or by the recommendation of the DSMB if serious
untoward events occur.
Safety monitoring
Careful baseline assessment will be conducted so as to
exclude potential participants who may experience ser-
ious adverse events, such as those with liver disease and
renal disease. Adverse effects of medications will be
monitored using biweekly (every two weeks) telephone
calls by a trained clinical nurse. Participants will be en-
couraged to visit between the biweekly telephone assess-
ments if they experience symptoms that are indicative of
troublesome side effects. According to the safety profile
of minocycline we expect very few side effects. In patients
who received minocycline for schizophrenia for up to
12 months, no serious side effects were encountered [24].
We have established a DSMB, independent of the clin-
ical trial, composed of a psychiatrist, pharmacologist, and
statistician. All serious adverse events will be reported
immediately to the DSMB and the Food, Medicine and
Healthcare Administration and Control Authority of
Ethiopia (EFMHACA) as well as the College of Health
Sciences, Institutional Review Board (IRB), and National
Research Ethics Review Committee (NERC). Minor ad-
verse events will be reported as part of the regular report-
ing requirements. We will also have a trial monitor, who
will be at least a general practitioner and would have train-
ing in Good Clinical Practice (GCP) and trial monitoring.
Ethical approval
Ethical approval is obtained from the IRB of Addis
Ababa University, College of Health Sciences (protocol
number: 062/11/Psy), NERC (Reference number: 310/
670/04), and the EFMHACA (reference number: 02/6/
05/39). Appropriate consent procedures will be followed
for the inclusion of participants in the study (Figure 1).
Drug encapsulation and storage
Drug encapsulation procedure is provided separately.
Both placebo and minocycline are formulated into
opaque capsules. Minocycline capsules contain 100 mg
of active ingredient and filler (Lactose NFP Powder) to
ensure capsules are secure; the placebo will contain only
filler in a total mass equal to that of the minocycline.
Transportation can be done by regular (non-refrigerated)
freight. Study drug will be stored at room temperature.
Reporting
Results of the study will be reported to the IRB of the
College of Health Sciences, the NERC, and EFMHACA
in addition to being published in scientific literature.
Trial status
Approval of the protocol has been obtained and recruit-
ment of patients will begin within 2 months.
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